Cosmo Pharmaceuticals N.V. (SWX:COPN)

Market Cap	1.52B +38.9%
Revenue (ttm)	96.99M -61.0%
Net Income	-3.36M
EPS	-0.21
Shares Out	16.19M
PE Ratio	n/a
Forward PE	1,365.39
Dividend	1.90 (2.02%)
Ex-Dividend Date	Apr 24, 2026

Volume	70,525
Average Volume	41,005
Open	93.40
Previous Close	93.90
Day's Range	89.00 - 93.40
52-Week Range	41.60 - 129.40
Beta	1.43
RSI	24.87
Earnings Date	Mar 9, 2026

About Cosmo Pharmaceuticals

Cosmo Pharmaceuticals N.V., a life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cor...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1997
• Employees: 332
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: COPN

Financial Performance

Financial numbers in EUR